Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-25T09:31:04.165Z Has data issue: false hasContentIssue false
  • English
  • Français

Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients

Published online by Cambridge University Press:  01 January 2021

George T. H. Ellison ,
Jay S. Kaufman ,
Rosemary F. Head ,
Paul A. Martin  and
Jonathan D. Kahn
Get access Rights & Permissions [Opens in a new window]

Extract

There is likely to be widespread agreement with much of the FDA’s rationale for approving BiDil (a combination of hydralazine hydrochloride and isosorbide dinitrate; H-I) as a treatment for heart failure. In particular, most would agree that the evidence of effectiveness provided by the African American Heart Failure Trial (A-HeFT) is compelling. Likewise, few health scientists would believe that it is either necessary or responsible to withhold therapies such as BiDil from those who might benefit until there is a full understanding of how they work. And although there is substantial concern that biomedical differences between racial groups are routinely misinterpreted as evidence of innate genetic differences (hence Jonathan Kahn’s call for all such claims to be supported by genetic evidence), most would concede that using race as a “descriptive” variable can help identify differences in health and access/response to treatment that might warrant further investigation or intervention.

Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 36 , Issue 3 , Fall 2008 , pp. 449 - 457
Copyright
Copyright © American Society of Law, Medicine and Ethics 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Temple, R. and Stockbridge, N. L., “BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective,” Annals of Internal Medicine 146, no. 1 (2007): 57–62.CrossRefGoogle Scholar
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D’Agostino, R., and Ferdinand, K., “Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure,” New England Journal of Medicine 351, no. 20 (2004): 2049–2057.CrossRefGoogle Scholar
Bibbins-Domingo, K. and Fernandez, A., “BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval,” Annals of Internal Medicine 146, no. 1 (2007): 52–56.CrossRefGoogle Scholar
Id.Google Scholar
Kahn, J., “How a Drug Becomes ‘Ethnic’: Law, Commerce, and the Production of Racial Categories in Medicine,” Yale Journal of Health Policy, Law & Ethics 4, no. 1 (2004): 1–46.Google Scholar
Ellison, G. T. H., Smart, A., Tutton, R., Outram, S. M., Ashcroft, R., and Martin, P., “Racial Categories in Medicine: A Failure of Evidence-Based Practice?” Public Library of Science Medicine 4, no. 9 (2007): 1434–1436.Google Scholar
Ellison, G. T. H., “Population Profiling and Public Health Risk: When and How Should We Use Race/Ethnicity?” Critical Public Health 15, no. 1 (2005): 65–74.CrossRefGoogle Scholar
See Temple, and Stockbridge, , supra note 1.Google Scholar
Id.Google Scholar
Carson, P., Ziesche, S., Johnson, G., and Cohn, J., “Racial Differences in Response to Therapy for Heart Failure: Analysis of the Vasodilator-Heart Failure Trials,” Journal of Cardiac Failure 5, no. 3 (1999): 178–187.CrossRefGoogle Scholar
See Bibbins-Domingo, and Fernandez, , supra note 3.Google Scholar
Cohn, J. N., Archibald, D. G., Ziesche, S., Cobb, F., Franciosa, J. A., and Harston, W. E. et al., “Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure: Results of a Veterans Administration Cooperative Study,” New England Journal of Medicine 314, no. 24 (1986): 1547–1552; Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., and Tristani, F. et al., “A Comparison of Enalapril with Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure,” New England Journal of Medicine 325, no. 5 (1991): 303–310.CrossRefGoogle Scholar
See Kahn, , supra note 5.Google Scholar
See Bibbins-Domingo, and Fernandez, , supra note 3.Google Scholar
Ellison, G. T. H., “Medicine in Black and White: BiDil, Race and the Limits of Evidence-Based Medicine,” Significance 3, no. 3 (2006): 118–121; Kent, D. and Hayward, R., “When Averages Hide Individual Differences in Clinical Trials,” American Scientist 95, no. 1 (2007): 60–68; Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., and Drazen, J. M., “Statistics in Medicine: Reporting of Subgroup Analyses in Clinical Trials,” New England Journal of Medicine 357, no. 21 (2007): 2189–2194.CrossRefGoogle Scholar
See Cohn, , Johnson, , Ziesche, , Cobb, , Francis, , and Tristani, et al., supra note 12.Google Scholar
See Cohn, , Archibald, , Ziesche, , Cobb, , Franciosa, , and Harston, et al., supra note 12.Google Scholar
See Cohn, , Johnson, , Ziesche, , Cobb, , Francis, , and Tristani, et al., supra note 12.Google Scholar
See Kent, and Hayward, , supra note 15.Google Scholar
See Carson, , Ziesche, , Johnson, , and Cohn, , supra note 10.Google Scholar
Id.Google Scholar
See Cohn, , Archibald, , Ziesche, , Cobb, , Franciosa, , and Harston, et al., supra note 12; Cohn, , Johnson, , Ziesche, , Cobb, , Francis, , and Tristani, et al., supra note 12; Cohn, J. N., Archibald, D. G., Francis, G. S., Ziesche, S., Franciosa, J. A., and Harston, W. E. et al., “Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: Influence of Pre-Randomization Variables on the Reduction of Mortality by Treatment with Hydralazine and Isosorbide Dinitrate,” Circulation 75, no. 5 (1987): IV49–IV54; Johnson, G., Carson, P., Francis, G. S., and Cohn, J. N., “Influence of Pre-Randomisation (Baseline) Variables on Mortality and on the Reduction of Mortality by Enalapril: Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II),” Circulation 87, no. 6 (1993): VI32–VI39.Google Scholar
See Temple, and Stockbridge, , supra note 1; Carson, , Ziesche, , Johnson, , and Cohn, , supra note 10.Google Scholar
Id. (Carson et al.)Google Scholar
Id.Google Scholar
Kaufman, J. S. and Cooper, R. S., “Considerations for Use of Racial/Ethnic Classification in a Etiologic Research,” American Journal of Epidemiology 514, no. 4 (2001): 291–298.CrossRefGoogle Scholar
See Carson, , Ziesche, , Johnson, , and Cohn, , supra note 10.Google Scholar
See Temple, and Stockbridge, , supra note 1, at 57.Google Scholar
See Taylor, , Ziesche, , Yancy, , Carson, , D’Agostino, , and Ferdinand, , supra note 2.Google Scholar
Khan, J. M. and Beevers, D. G., “Management of Hypertension in Ethnic Minorities,” Heart 91, no. 8 (2005): 1105–1109.CrossRefGoogle Scholar
See Temple, and Stockbridge, , supra note 1.Google Scholar
Id.Google Scholar
Id.Google Scholar
See Ellison, , supra note 7; Editorial, “Census, Race and Science,” Nature Genetics 24, no. 2 (2000): 97–98.Google Scholar
See Kahn, , supra note 5.Google Scholar
See Temple, and Stockbridge, , supra note 1, at 58.Google Scholar
See Ellison, , supra note 7.Google Scholar
See Temple, and Stockbridge, , supra note 1, at 61.Google Scholar
See also La Parra Casado, D. and Perez, A. M., “Scientifically Correct Racism: Health Studies’ Unintentional Effects Against Minority Groups,” Language and Intercultural Communication 7, no. 2 (2007): 152–162.CrossRefGoogle Scholar
NIH Revitalization Act, Pub. L. No. 103–43 (1993).Google Scholar
See Temple, and Stockbridge, , supra note 1, at 60.Google Scholar
Id., at 60.Google Scholar
See Kahn, , supra note 5.Google Scholar
See “NitroMed Reports Financial Results for First Fiscal Quarter 2008,” availaible at <http://phx.corporate-ir.net/phoenix.zhtml?c=130535&p=irol-newsArticle&ID=1141115&highlight=> (last visited May 20, 2008).+(last+visited+May+20,+2008).>Google Scholar
See Temple, and Stockbridge, , supra note 1, at 61.Google Scholar
Martin, P. A., Lewis, G., Smart, A., and Webster, A., False Positive? Prospects for the Clinical and Commercial Development of Pharmacogenetics (Nottingham and York: University of Nottingham and University of York, 2006).Google Scholar
See Temple, and Stockbridge, , supra note 1, at 61.Google Scholar
Center for Drug Evaluation and Research, “Approval Package for: Application Number NDA 20–727. Administrative/Correspondence Reviews. N.d.,” available at <http://www.fda.gov/cder/foi/nda/2005/020727_S000_Bidil_AdminCorres.pdf> (last visited May 19, 2008).+(last+visited+May+19,+2008).>Google Scholar